Stefan Blochlinger

Showing 1-2 of 2 articles

Coronary interventions

Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction

Pilgrim T, Piccolo R, Heg D, Roffi M, Tüller D, Vuilliomenet A, Mueller O, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Khattab A, Taniwaki M, Rigamonti F, Nietlispach F, Blochlinger S, Wenaweser P, Jüni P, Windecker S

December 9, 2016 | 10.4244/EIJY15M12_09

Predictors of adverse events among patients undergoing primary percutaneous coronary intervention: insights from a pooled analysis of the COMFORTABLE AMI and EXAMINATION trials

Taniwaki M, Stefanini G, Räber L, Brugaletta S, Cequier A, Heg D, Iñiguez A, Kelbæk H, Serra A, Ostojic M, Hernández-Antolín R, Baumbach A, Blochlinger S, Jüni P, Mainar V, Sabaté M, Windecker S

August 20, 2015 | 10.4244/EIJY14M07_12

1

Latest news

TAVI dysfunction, coronary sinus narrowing, carotid interventions through the snuffbox, and more

CT image showing a case of valve thrombosis after ViV TAVI

February 20, 2020

Will Your Heart Team EXCEL?

February 20, 2020

This Weeks JAA's: SAFE-A study, Coronary access after TAVR-in-TAVR and much more

February 25, 2020

New Update: CULPRIT, NOBEL, IVUS-XPL, SAFARI-STEMI

(supported by Biotronik)

February 14, 2020

Guidance Papers

Guidelines, consensus & position papers

New ahead of print: Validation of ARC-HBR criteria

February 18, 2020

New Editor-in-Chief editorial: Moving forward

Davide Capodanno

February 7, 2020

Coronary

Valvular disease

Heart failure

Peripheral

Hypertension

Stroke